SCHEMBL8496933

SCHEMBL8496933

CC(=O)OCC(=O)N1CCN(C)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ MAPT P10636 2/20 0.49
▸ TP53 P04637 2/20 0.49
▸ POLB P06746 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ GAA P10253 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HTR1A P08908 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ CASP1 P29466 1/20 0.40
▸ CASP7 P55210 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26828140 0.86 ALDH1A1 (0.50) TDP1CYP1A2ALDH1A1MAPTTP53
SCHEMBL18780592 0.83 RAB9A (0.53) ALDH1A1MAPTTP53SMN1; SMN2RAB9A
SCHEMBL2025855 0.83 RAB9A (0.49) TDP1ALDH1A1MAPTTP53SMN1; SMN2
SCHEMBL14012787 0.83 ALDH1A1 (0.46) ALDH1A1MAPTTP53POLBSMN1; SMN2
SCHEMBL14567934 0.82 ALDH1A1 (0.48) ALDH1A1MAPTTP53POLBL3MBTL1
SCHEMBL12251951 0.82 ALDH1A1 (0.45) ALDH1A1MAPTTP53POLBL3MBTL1
SCHEMBL13996243 0.82 RAB9A (0.51) ALDH1A1MAPTTP53POLBSMN1; SMN2
SCHEMBL25437213 0.81 ALDH1A1 (0.43) ALDH1A1MAPTTP53L3MBTL1SMN1; SMN2
SCHEMBL14871086 0.81 ALDH1A1 (0.47) ALDH1A1MAPTTP53POLBSMN1; SMN2
SCHEMBL29190317 0.81 TPSAB1 (0.51) ALDH1A1MAPTTP53POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943795-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2011-05-17 — — US disclosed
US-7943795-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2011-05-17 — — US disclosed
US-7897789-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2011-03-01 — — US disclosed
US-7897789-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2011-03-01 — — US disclosed
US-7772425-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2010-08-10 — — US disclosed
US-7772425-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2010-08-10 — — US disclosed
US-7750184-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2010-07-06 — — US disclosed
US-7750184-B2 Vitamin D receptor modulators ELI LILLY AND COMPANY (US) 2010-07-06 — — US disclosed
EP-2184281-A1 Phenyl-thiophene type vitamin D receptor modulators Eli Lilly & Company (US) 2010-05-12 — — EP disclosed
US-20100076065-A1 VITAMIN D RECEPTOR MODULATORS LU JIANLIANG 2010-03-25 — — US disclosed
US-20080027037-A1 Cyclic compounds TANABE SEIYAKU CO., LTD. 2008-01-31 — — US disclosed
US-7273868-B2 Pyrazine derivatives TANABE SEIYAKU CO., LTD. (JP) 2007-09-25 — — US disclosed
US-7273868-B2 Pyrazine derivatives TANABE SEIYAKU CO., LTD. (JP) 2007-09-25 — — US disclosed
US-20070149810-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY (US) 2007-06-28 — — US disclosed
US-20070149810-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY (US) 2007-06-28 — — US disclosed
US-7220736-B2 Pyrimidine compounds TANABE SEIYAKU CO., LTD. (JP) 2007-05-22 — — US disclosed
US-7220736-B2 Pyrimidine compounds TANABE SEIYAKU CO., LTD. (JP) 2007-05-22 — — US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 — — US disclosed
US-20070106095-A1 Vitamin d receptor modulators ELI LILLY AND COMPANY 2007-05-10 — — US disclosed
EP-1277741-A1 CYCLIC COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2003-01-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076065-A1 VITAMIN D RECEPTOR MODULATORS VDR, CYP2R1, CYP24A1 TDP1 4642/4885CYP1A2 1035/4885ALDH1A1 2594/4885
US-20070106095-A1 Vitamin d receptor modulators VDR, CYP2R1, CYP24A1 TDP1 4642/4885CYP1A2 1058/4885ALDH1A1 2576/4885
US-20070149810-A1 Vitamin d receptor modulators VDR, CYP2R1, CYP24A1 TDP1 4642/4885CYP1A2 1035/4885ALDH1A1 2594/4885
US-20080027037-A1 Cyclic compounds PDE4A, PDE4B, PDE3B TDP1 2014/4885CYP1A2 812/4885ALDH1A1 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback